We previously reported that the primary tumour/vessel tumour/nodal tumour (PVN) classification is significantly superior to the UICC pTNM classification ([@bib20]), the Nottingham Prognostic Index ([@bib22]; [@bib21]), and the histologic grade ([@bib4]) for accurately predicting the outcome of patients with invasive ductal carcinoma of the breast in a manner that is independent of the nodal status and the hormone receptor status ([@bib14]). Since then, we newly devised a histological prognostic system, namely a grading system for lymph vessel tumour emboli, and have clearly demonstrated that this grading system can accurately predict the outcome of patients with invasive ductal carcinoma in a manner that is independent of nodal metastasis ([@bib16], [@bib8]). In addition, although we have already reported that the diameter of the fibrotic focus is an important histological factor for predicting the outcome of patients with invasive ductal carcinoma without nodal metastasis ([@bib15], [@bib9]), this parameter was also found to be an important outcome predictor for patients with invasive ductal carcinoma with nodal metastasis in a study with a different patient group ([@bib17]). Although we have separately devised a PVN classification based on histological factors, for example, the diameter of the fibrotic focus, the number of apoptotic figures of lymph vessel tumour emboli, and the number of invaded lymph vessels, for accurately predicting the outcome of patients with invasive ductal carcinoma with or without nodal metastasis ([@bib14]), the above-mentioned studies strongly suggested that the factors used in this classification can accurately predict the outcome of patients with invasive ductal carcinoma in a manner that is independent of the nodal status. Thus, we attempted to refine the PVN classification using well-known histological factors as well as the factors that we proposed by analysing the outcome predictive powers of these factors in a different invasive ductal carcinoma patient group.

The purpose of this study was to compare the outcome predictive power of the modified PVN classification with that of the newly devised pathological UICC pTNM classification ([@bib19]), and the reclassified Nottingham Prognostic Index ([@bib2]) in a different group of patients with invasive ductal carcinoma. The latter two classifications are the major histological prognostic classifications currently in use clinically to predict the outcome of patients with breast carcinoma. The results clearly indicated that the modified PVN classification is a useful histological classification available for predicting the outcome of invasive ductal carcinoma of the breast in a manner that is independent of the nodal status, the hormone receptor status, and the adjuvant therapy status.

Patients and methods
====================

Patients
--------

The subjects of this study were 1042 consecutive patients with invasive ductal carcinoma of the breast who did not receive neoadjuvant therapy and were selected among 1759 patients with breast cancer who were surgically treated at the National Cancer Center Hospital between January 2000 and December 2005 (almost the same case series as that used in our previous study)([@bib8]). The invasive ductal carcinomas were diagnosed preoperatively using a needle biopsy, aspiration cytology, a mammography, or ultrasonography. All the patients investigated in this study were Japanese women, ranging in age from 23 to 72 years old (median, 55 years). All had a solitary lesion; 498 patients were pre-menopausal and 544 were post-menopausal. A partial mastectomy had been performed in 458 patients, and a modified radical mastectomy had been performed in 584. A level I and level II axillary lymph node dissection had been performed in all the patients, and a level III axillary lymph node dissection had been performed in some of the invasive ductal carcinoma patients.

Of the 1042 patients, 873 received adjuvant therapy, consisting of chemotherapy in 217 patients, endocrine therapy in 281 patients, and chemoendocrine therapy in 375 patients. The chemotherapy regimens used were anthracycline-based with or without taxane and non-anthracycline-based, and the endocrine therapy regimens consisted of tamoxifen with or without a gonadotropin-releasing hormone agonist, tamoxifen, with or without an aromatase inhibitor, an aromatase inhibitor alone, or a gonadotropin-releasing hormone agonist alone. No cases of inflammatory breast cancer were included in this series. All the tumours were classified according to the pathological UICC TNM classification ([@bib19]). The protocol for this study (20--112) was reviewed by the institutional review board of the National Cancer Center.

For the pathological examination, the surgically resected specimens were fixed in 10% formalin, and the size and gross appearance of the tumours were recorded. The tumour size was confirmed by comparison with the tumour size on the histological slides.

Improvement of the PVN classification
-------------------------------------

We previously reported that a grading system for lymph vessel tumour emboli is a very useful histological classification in the accurate prediction of the outcome of patients with invasive ductal carcinoma independent of nodal status using multivariate analyses with well-known clinicopathological factors ([@bib16], [@bib8]). Furthermore, the diameter of the fibrotic focus has also been reported to be a useful histological predictor of outcome for invasive ductal carcinoma patients with or without nodal metastasis using multivariate analyses with well-known clinicopathological factors ([@bib17]). Thus, based on these findings, we attempted to improve our original PVN classification ([@bib14]) by performing multivariate analyses using the Cox proportional hazard regression model to analyse the effects of well-known histological factors, our proposed histological factors, age (⩽39 *vs* \>39 years), the Allred scores for oestrogen receptor and progesterone receptor and the category of HER2 expression in the tumour cells, and the type of adjuvant therapy (no adjuvant therapy, endocrine therapy, chemoendocrine therapy, and chemotherapy). Factors that were significantly associated with outcome in univariate analyses were entered together into a multivariate analysis performed using the Cox proportional hazard regression model. The case-wise, step-down, and two-sided method was applied until all the remaining factors were significant at a *P*-value of \<0.05. All analyses were performed using Statistica/Windows software (StatSoft, Tulsa, OK, USA).

The following 12 histological factors of the primary invasive ductal carcinomas were evaluated: (1) invasive tumour size (⩽20 mm, \>20 to ⩽50 mm, and \>50 mm), (2) tubule formation (well degree, moderate degree, and poor degree) ([@bib4]), (3) number of mitotic figures in the primary invasive ductal carcinoma (⩽9, \>9 to ⩽19, and \>20) ([@bib4]), (4) nuclear features (small and regular, moderate variation, and marked variation) ([@bib4]), (5) tumour necrosis (absent and present)([@bib5]), (6) blood vessel invasion (absent and present), (7) adipose tissue invasion (absent and present), (8) skin invasion (absent and present), (9) muscle invasion (absent and present), (10) fibrotic focus (absent, fibrotic focus diameter ⩽8 mm, and fibrotic focus diameter \>8 mm)([@bib15], [@bib9]), (11) grading system for lymph vessel tumour emboli (grades 0, 1, 2, and 3) ([@bib16], [@bib8]), and (12) number of apoptotic figures in blood vessel tumour emboli (blood vessel invasion absent, ⩽2, and \>2) ([@bib10]).

The nodal metastases were evaluated using single sections of each node or half of each node stained with hematoxylin and eosin. The following 10 histological parameters of metastatic mammary carcinoma to the lymph nodes were evaluated: (1) number of nodal metastases (no nodal metastasis, 1--3, 4--9, 10, or more), (2) maximum dimension (no nodal metastasis, ⩽20 mm, and \>20 mm), (3) tubule formation (no nodal metastasis, well degree, moderate degree, and poor degree), (4) nuclear features (no nodal metastasis, small and regular, moderate variation, and marked variation), (5) number of mitotic figures (no nodal metastasis, ⩽5, and \>5)([@bib11], [@bib12], [@bib7]), (6) fibrotic focus (no nodal metastasis, absent, and present), (7) tumour necrosis (no nodal metastasis, absent, and present), (8) grade of stromal fibrosis (no nodal metastasis, none, mild, moderate, and severe) ([@bib11], [@bib12], [@bib7]), (9) number of lymph nodes with extranodal invasion (no nodal metastasis, ⩽5, and \>5) ([@bib11], [@bib12], [@bib7]), and (10) number of extranodal blood vessel tumour emboli (no nodal metastasis, \<2, and \>2) ([@bib11], [@bib12], [@bib7]). We randomly searched for mitotic figures in metastatic mammary carcinoma to the lymph nodes using mid-power magnification fields ( × 10 or × 20) of the tumour area and selected one high-power magnification field ( × 40) of the tumour area with the highest number of mitotic figures in metastatic mammary carcinoma to the lymph nodes to determine the largest number of metastatic mammary carcinoma to the lymph nodes exhibiting mitotic figures ([Figure 1](#fig1){ref-type="fig"}). The tubule formation, nuclear features, and presence of tumour necrosis in metastatic mammary carcinoma to the lymph nodes were evaluated in the same manner as for the primary invasive ductal carcinomas.

Prognostic histological classifications for comparative study
-------------------------------------------------------------

The following existing histological classifications were compared with our modified classification with regard to the prediction of disease-free survival and overall survival: (1) the UICC pTNM classification ([@bib19]) and (2) the Nottingham Prognostic Index ([@bib2]).

The Nottingham Prognostic Index ([@bib2]) is based on the tumour size, histologic grade ([@bib4]), and nodal classification of the UICC pTNM classification ([@bib19]). Thus, multivariate analyses for tumour recurrence and tumour-related death were performed using the following models to avoid the mutual influences of each classification: (1) model 1, the modified PVN classification and the UICC pTNM classification; and (2) model 2, the modified PVN classification and the Nottingham Prognostic Index.

The predictive powers for the disease-free and overall survivals of each classification, age (⩽39 *vs* \>39 years), the Allred scores for oestrogen receptor and progesterone receptor and the category of HER2 expression in the tumour cells, and the type of adjuvant therapy (no adjuvant therapy, endocrine therapy, chemoendocrine therapy, and chemotherapy) were evaluated using univariate analyses with the Cox proportional hazard regression model according to nodal status, hormone receptor status, and adjuvant therapy status. The classifications and factors that were significantly associated with outcome in the univariate analyses were then entered together into the multivariate analyses that were performed using the Cox proportional hazard regression model. The case-wise, step-down and two-sided method was applied until all the remaining factors were significant at a *P*-value of \<0.05. The survival curves were drawn using the Kaplan--Meier method. All the analyses were performed with Statistica/Windows software (StatSoft).

Assessment of oestrogen receptor, progesterone receptor, and HER2 expression
----------------------------------------------------------------------------

Slides of the tumour cells immunostained for oestrogen receptor or progesterone receptor were scored using the Allred scoring system, as described previously ([@bib6]; [@bib18]), and the Allred scores for oestrogen receptor and progesterone receptor in the tumour cells were classified into the following three categories ([@bib17]): (1) Allred score for oestrogen receptor in tumour cells (0 or 2, 3--6, and 7 or 8); and (2) Allred score for progesterone receptor in tumour cells (0 or 2, 3--6, and 7 or 8). The HER2 status of the tumour cells was semiquantitatively scored on a scale of 0--3 according to the level of HER2 protein expression ([@bib23]) and was classified into three categories: 0 or 1, 2, and 3.

Patient outcome
---------------

Survival was evaluated using a median follow-up period of 98 months (range: 63--134 months) until March 2011. Of the 1042 invasive ductal carcinoma patients, 858 patients were alive and well, 184 had developed tumour recurrences (distant-organ metastasis and local recurrence), and 89 had died of their disease. The tumour recurrence-free survival and overall survival periods were calculated using the time of surgery as the starting point. Tumour relapse was considered to have occurred whenever evidence of distant-organ metastasis or local recurrence was found.

Results
=======

Histological factors significantly associated with the outcome of patients with invasive ductal carcinoma
---------------------------------------------------------------------------------------------------------

Among all the patients with invasive ductal carcinoma, a fibrotic focus diameter \>8 mm, lymph vessel tumour embolus grades 2 and 3, lymph node metastases with a dimension of \>20 mm, \>2 apoptotic figures in blood vessel tumour emboli, and \>5 mitotic figures in metastatic carcinoma to the lymph nodes had significantly higher hazard ratios for tumour recurrence and tumour-related death in multivariate analyses ([Table 1](#tbl1){ref-type="table"}). Marked variation in the nuclear features of the primary invasive ductal carcinoma had a significantly higher hazard ratio for tumour recurrence, and \>2 extranodal blood vessel tumour emboli had a significantly higher hazard ratio for tumour-related death in multivariate analyses ([Table 1](#tbl1){ref-type="table"}). An Allred score of 7 or 8 for progesterone receptor in the tumour cells had a significantly lower hazard ratio for tumour-related death in multivariate analysis ([Table 1](#tbl1){ref-type="table"}).

Among patients with invasive ductal carcinoma without nodal metastasis, lymph vessel tumour grade 3 and \>19 mitotic figures in primary invasive ductal carcinomas had a significantly higher hazard ratio for tumour recurrence and tumour-related death in multivariate analyses ([Table 2](#tbl2){ref-type="table"}). Lymph vessel tumour grade 2, a fibrotic focus \>8 mm, and HER2 category 3 had significantly higher hazard ratios for tumour recurrence, and \>2 apoptotic figures in blood vessel tumour emboli had a significantly higher hazard ratio for tumour-related death in multivariate analyses.

Among patients with invasive ductal carcinoma with nodal metastases, a fibrotic focus diameter \>8 mm, lymph vessel tumour embolus grades 2 and 3, lymph node metastases with a dimension of \>20 mm, \>2 apoptotic figures in blood vessel tumour emboli, \>2 extranodal blood vessel tumour emboli, and \>5 mitotic figures in metastatic carcinoma to the lymph nodes had significantly higher hazard ratios for tumour recurrence and tumour-related death in multivariate analyses ([Table 3](#tbl3){ref-type="table"}). A severe grade of stromal fibrosis in metastatic carcinoma to the lymph nodes had a significantly higher ratio for tumour recurrence, and an Allred score of 7 or 8 for progesterone receptors had a significantly lower hazard ratio for tumour-related death in a multivariate analysis ([Table 3](#tbl3){ref-type="table"}).

Modified PVN classification
---------------------------

We refined our previously proposed PVN classification ([@bib14]) based on the above results of the present study, and the nine parameters that were selected for modified PVN classification are listed in [Table 4](#tbl4){ref-type="table"} ([Figure 1](#fig1){ref-type="fig"}). Four factors (mitotic figures in primary invasive ductal carcinoma, lymph vessel tumour grade, grade of stromal fibrosis in metastatic carcinoma to the lymph nodes, and maximum dimension of metastatic carcinoma to the lymph nodes) were newly added to the classification based on the results of this study. In the modified PVN classification, a score of 1 point was given for each unfavourable parameter. A grading system of 0--3 was used to score the lymph vessel tumour emboli ([@bib16], [@bib8]) ([Figure 1D](#fig1){ref-type="fig"}). The total score was then calculated (0--11). The resulting scores were divided into the following six classes according to their significant associations with tumour recurrence or tumour-related death in univariate analyses using the logrank test: (1) class 0 (score 0), (2) class 1 (scores 1 and 2), (3) class 2 (scores 3 and 4), (4) class 3 (score 5), (5) class 4 (scores 6 and 7), and (6) class 5 (score of 8 or more) ([Table 5](#tbl5){ref-type="table"}, [Figure 2](#fig2){ref-type="fig"}).

Furthermore, we also attempted to modify the PVN classification using the weight given to each factor based on its median hazard ratio obtained using the multivariate analyses in this study. The weights that were given for each factor were as follows: (1) 2.0 for a fibrotic focus diameter \>8 mm, (2) 1.5 for the marked variation of nuclear features of primary invasive ductal carcinoma, (3) 7.2 for \>19 mitotic figures in primary invasive ductal carcinoma, (4) 2.9 for lymph vessel tumour embolus grade 2 and 4.2 for lymph vessel tumour embolus grade 3, (5) 3.2 for \>2 apoptotic figures in blood vessel tumour emboli, (6) 1.9 for a severe grade of stromal fibrosis in metastatic carcinoma to the lymph nodes, (7) 1.9 for lymph node metastases with a dimension of \>20, (8) 1.9 for \>2 extranodal blood vessel tumour emboli, and (9) 3.1 for \>5 mitotic figures in metastatic carcinoma to the lymph nodes. The total factor weights for individual patients were calculated (minimum, 0; maximum, 27.3; median, 1.5) and we classified all the patients into the following five classes based on the total factor weight for each patient: (1) 484 patients with a total factor weight of 0, class 0; (2) 192 with a total factor weight of \>0 to ⩽5, class 1; (3) 321 with a total factor weight of \>5 to ⩽10, class 2; (4) 31 with a total factor weight of \>10 to ⩽18, class 3; and (5) 14 with a total factor weight of \>18, class 4.

Next, we performed multivariate analyses for tumour recurrence and tumour-related death between the score-modified PVN and the weight-modified PVN classification as a whole. Although both classifications significantly increased the hazard ratios for tumour recurrence and tumour-related death, the score-modified PVN classification (tumour recurrence: trend hazard ratio, 2.1, *P*\<0.001; tumour-related death: trend hazard ratio, 2.2, *P*\<0.001) had higher trend hazard ratios and lower trend *P*-values for tumour recurrence and tumour-related death than the weight-modified PVN classification (tumour recurrence: trend hazard ratio, 1.3, *P*=0.019; tumour-related death: trend hazard ratio, 1.5, *P*=0.033). Therefore, we adopted the former classification for a comparison with the other two classifications in this study.

Tumour recurrence and death rates according to each classification
------------------------------------------------------------------

According to the modified PVN classification, the rates of tumour recurrence or death from invasive ductal carcinoma increased as the order of the classes increased; the rates of classes 4 and 5, in particular, were higher than those of the high-risk groups of the other classifications ([Table 5](#tbl5){ref-type="table"}). Significantly shorter crude disease-free survival and overall survival periods were observed according to the increasing order of classes, with the exception of both survival periods for classes 3 and 4 and the overall survival periods for classes 4 and 5 ([Table 5](#tbl5){ref-type="table"}, [Figure 2](#fig2){ref-type="fig"}).

Among the other classifications, the UICC pTNM stage classification showed significantly shorter crude disease-free survival and overall survival periods according to the increasing order of stages ([Table 5](#tbl5){ref-type="table"}). Among the three classifications, the Nottingham Prognostic Index clearly exhibited the lowest tumour recurrence rate in patients with a good prognosis (excellent prognostic group). The Nottingham Prognostic Index showed a significantly shorter crude disease-free survival period according to the increasing order of groups with the exception of moderate prognostic group II, but significant differences in the overall survival periods were seen between the moderate prognostic group II and the poor prognostic group, and between the poor prognostic group and the very poor prognostic group out of the six groups ([Table 5](#tbl5){ref-type="table"}).

Comparison of the classifications
---------------------------------

In model 1 multivariate analyses of all the patients, the modified PVN classification significantly increased the trend hazard ratios for tumour recurrence (*P*\<0.001) and tumour-related death (*P*\<0.001). Although the UICC pTNM classification showed a significant association with tumour recurrence (*P*=0.018), it failed to show a significant association with tumour-related death (*P*=0.165). HER2 category 3 had a significant association with tumour recurrence (*P*=0.033). In model 2 multivariate analyses, the modified PVN classification significantly increased the trend hazard ratios for tumour recurrence (*P*\<0.001) and tumour-related death (*P*\<0.001). The Nottingham Prognostic Index also showed significant associations with tumour recurrence (*P*=0.003) and tumour-related death (*P*=0.006). HER2 category 3 failed to significantly increase the hazard ratio for tumour recurrence in model 2 multivariate analyses.

In patients with invasive ductal carcinoma without nodal metastasis, the UICC pTNM classification failed to show a significant association with tumour recurrence or tumour-related death in univariate analyses (data not shown). In model 1 multivariate analyses, the modified PVN classification was significantly associated with tumour recurrence (*P*\<0.001) and tumour-related death (*P*\<0.001). In model 2 multivariate analyses, the modified PVN classification was significantly associated with tumour recurrence and tumour-related death, but the Nottingham Prognostic Index was not significantly associated with tumour recurrence or tumour-related death ([Table 6](#tbl6){ref-type="table"}).

In patients with invasive ductal carcinoma with nodal metastasis, the modified PVN classification showed significant associations with tumour recurrence and tumour-related death but the UICC pTNM classification did not show a significant association with tumour recurrence or tumour-related death in model 1 multivariate analyses ([Table 6](#tbl6){ref-type="table"}). In model 2 multivariate analyses, the modified PVN classification also showed significant associations with tumour recurrence and tumour-related death. The Nottingham Prognostic Index did not show a significant association with tumour recurrence, but a significant association with tumour-related death was observed ([Table 6](#tbl6){ref-type="table"}).

In patients with invasive ductal carcinoma who were completely negative for hormone receptors, only the modified PVN classification showed significantly increasing trend hazard ratios for tumour recurrence and tumour-related death in the multivariate analyses ([Table 6](#tbl6){ref-type="table"}).

In model 1 and 2 multivariate analyses of patients with invasive ductal carcinoma who were positive for one or two hormone receptors, the modified PVN classification exhibited significantly increasing trend hazard ratios for tumour recurrence and tumour-related death ([Table 6](#tbl6){ref-type="table"}). The Nottingham Prognostic Index also showed significantly increasing trend hazard ratios for tumour recurrence and tumour-related death ([Table 6](#tbl6){ref-type="table"}). Although the UICC pTNM classification significantly increased the trend hazard ratio for tumour recurrence, it failed to significantly increase the trend hazard ratio for tumour-related death ([Table 6](#tbl6){ref-type="table"}). In model 1 and 2 multivariate analyses, the adjuvant therapy status significantly increased the trend hazard ratios for tumour-related death (model 1, *P*=0.007; model 2, *P*=0.022) but failed to significantly increase the trend hazard ratios for tumour recurrence (model 1, *P*=0.996; model 2, *P*=0.597).

In model 1 and 2 multivariate analyses of patients with invasive ductal carcinoma not treated with adjuvant therapy, the modified PVN classification significantly increased the hazard ratios for tumour recurrence ([Table 7](#tbl7){ref-type="table"}). The UICC pTNM classification and the Nottingham Prognostic Index failed to show significant associations with tumour recurrence ([Table 7](#tbl7){ref-type="table"}). HER2 category 3 significantly increased the trend hazard ratio for tumour recurrence in a model 1 multivariate analysis (*P*=0.048) but failed to significantly increase the trend hazard ratio for tumour recurrence in a model 2 multivariate analysis (*P*=0.093). As only five patients died as a result of their disease in this series, a multivariate analysis for tumour-related death could not be performed.

In model 1 and 2 multivariate analyses of patients with invasive ductal carcinoma treated with endocrine therapy, the modified PVN classification significantly increased the trend hazard ratios for tumour recurrence and tumour-related death ([Table 7](#tbl7){ref-type="table"}). The UICC pTNM classification and the Nottingham Prognostic Index failed to show significant associations with tumour recurrence and tumour-related death ([Table 7](#tbl7){ref-type="table"}). In model 1 and 2 multivariate analyses, HER2 category 3 significantly increased the trend hazard ratios for tumour-related death (model 1 and model 2, *P*\<0.001) but failed to significantly increase the trend hazard ratios for tumour recurrence (model 1, *P*=0.082; model 2, *P*=0.086).

In model 1 and 2 multivariate analyses of patients with invasive ductal carcinoma treated with chemoendocrine therapy, the modified PVN classification significantly increased the hazard ratios for tumour recurrence and tumour-related death ([Table 7](#tbl7){ref-type="table"}). The UICC pTNM classification did not show significantly increasing trend hazard ratios for tumour recurrence and tumour-related death ([Table 7](#tbl7){ref-type="table"}). The Nottingham Prognostic Index significantly increased the trend hazard ratios for tumour recurrence and tumour-related death ([Table 7](#tbl7){ref-type="table"}).

In model 1 and 2 multivariate analyses of patients with invasive ductal carcinoma treated with chemotherapy, although the modified PVN classification significantly increased the trend hazard ratios for tumour recurrence and tumour-related death, the UICC pTNM classification and the Nottingham Prognostic Index failed to show significant associations with tumour recurrence or tumour-related death ([Table 7](#tbl7){ref-type="table"}).

Discussion
==========

We previously reported that the PVN classification can accurately predict the outcome of patients with invasive ductal carcinoma in a manner that is independent of the nodal status or hormone receptor status ([@bib14]), and the present study also clearly demonstrated that the modified PVN classification accurately predicted the outcome of patients with invasive ductal carcinoma in a manner that was independent of the nodal status, hormone receptor status, or adjuvant therapy status in a different group of patients with invasive ductal carcinoma. The clinical value of prognostic factors is particularly useful for the selection of different treatment regimens, especially adjuvant therapy in patients with invasive ductal carcinoma. One could argue that identifying patients with invasive ductal carcinoma who have a good prognosis and who do not require adjuvant therapy is of particular importance. The modified PVN classification was capable of classifying 815 (78%) out of 1042 patients as class 0 or 1, and patients belonging to these classes may be considered as good and moderately good prognostic groups, respectively. In contrast, patients belonging to class 2 or higher classes of the modified PVN classification may be considered as belonging to poor or very poor prognostic groups, respectively. In addition, the modified PVN classification had a superior outcome predictive power for the other two classifications in a manner that was independent of the adjuvant therapy status. Thus, the results of this study suggest that patients belonging to class 0 or 1 of the modified PVN classification can be spared adjuvant therapy, while patients belonging to class 2 or higher classes of the classification should be treated with adjuvant therapy in a manner that is independent of the nodal status or the hormone receptor status.

The factors included in the modified PVN classification were selected based on the precise analyses of this study using well-known clinicopathological factors, such as histologic grade, invasive tumour size, and nodal status. Among the nine factors in the modified PVN classification, seven of them were the histological factors that we proposed for primary invasive ductal carcinoma, carcinomas in vessels, and metastatic carcinoma to the lymph nodes ([@bib15], [@bib9], [@bib10], [@bib11], [@bib12], [@bib16], [@bib8], [@bib7]). This study clearly confirmed that these histological factors are important outcome predictors for different patient series of invasive ductal carcinoma of the breast. Among them, the outcome predictive power of the fibrotic focus among patients with invasive ductal carcinoma has also been confirmed by other investigators ([@bib3]; [@bib1]). Thus, these parameters are likely to be the most suitable parameters for accurately assessing the true biological malignant potential of invasive ductal carcinomas. In addition, we also confirmed the prognostic significance of the following factors that were previously reported by other investigators ([@bib4]) to be useful histological factors for predicting the outcome of patients with invasive ductal carcinomas: (1) the nuclear features of primary invasive ductal carcinoma and (2) the number of mitotic figures in primary invasive ductal carcinoma. Thus, the modified PVN classification appears to be better at accurately predicting the outcome of patients with invasive ductal carcinoma, compared with the other two classifications.

This study also strongly suggests that the tumour characteristics of invasive ductal carcinomas matter more than the quantity of tumour with regard to the accurate prediction of the outcome of patients with invasive ductal carcinoma. Both the UICC pTNM stage classification and the Nottingham Prognostic Index evaluate the malignant potential of invasive ductal carcinomas based on the invasive tumour size and the number of nodal metastases. These factors reflect the quantity of invasive ductal carcinoma cells. In contrast, almost all the factors in the modified PVN classification, exception of the maximum diameter of lymph node metastases, represent the tumour characteristics of invasive ductal carcinomas. In addition, we previously showed that mitotic figures and apoptotic figures in tumour cells of lymph vessel tumour emboli have significantly stronger outcome predictive powers than the number of lymph vessels that have been invaded ([@bib13]), and we devised a grading system for lymph vessel tumour emboli based on the presence of mitotic figures and apoptotic figures in the tumour cells of lymph vessel tumour emboli ([@bib16], [@bib8]). As the modified PVN classification can evaluate the tumour characteristics of the invasive ductal carcinoma more precisely than the other two classifications, it appears to have a superior ability for accurately predicting patient outcome. Therefore, we concluded that the modified PVN classification is a useful prognostic histological classification available for predicting the outcome of patients with invasive ductal carcinoma of the breast.

We used the modified PVN classification for patients with invasive ductal carcinoma because our previous studies clearly demonstrated that the factors included in this classification were significant outcome predictors only for patients with invasive ductal carcinoma ([@bib15], [@bib9], [@bib10], [@bib11], [@bib12], [@bib16], [@bib8], [@bib7]). The UICC pTNM classification and the Nottingham Prognostic Index can be applied to all invasive breast carcinomas and may be superior to the modified PVN classification for predicting the outcome of overall patients with invasive carcinoma. Thus, we should confirm whether the modified PVN classification is also able to accurately predict the outcome of patients with non-ductal carcinomas of the breast in the future.

In conclusion, the current study clearly confirmed that the modified PVN classification is a useful histological classification for predicting the outcome of patients with invasive ductal carcinoma of the breast. Thus, pathologists should attempt to assess the true malignant potential of invasive ductal carcinomas using the criteria of the modified PVN classification.
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![Histological factors of the modified PVN classification (**A**--**G**). (**A**) Invasive ductal carcinomas with a fibrotic focus. A fibrotic focus measuring 13.4 × 6.8 mm is visible within the tumour (panoramic view, arrows). The fibrotic focus shows a scar-like feature and is surrounded by invasive ductal carcinoma cells. (**B**) Invasive ductal carcinoma cells showing marked variations in nuclear features; mitotic figures are also visible in the tumour cells. (**C**) Several apoptotic bodies and apoptotic tumour cells are visible (arrows), and three mitotic tumour cells (arrowheads) are visible in the tumour embolus in the lymph vessel. (**D**) One blood vessel tumour embolus is seen adjacent to one artery. Seven apoptotic bodies or apoptotic tumour cells are seen in the blood vessel tumour embolus, and red blood cells are also visible. (**E**) Lymph node metastases exhibited a severe grade of tumour stroma. (**F**) Five extranodal blood vessel tumour emboli are seen in metastatic carcinoma to the lymph node (arrows). (**G**) Six mitotic tumour cells are visible in the tumour of the lymph node (arrows).](bjc2011279f1){#fig1}

![Disease-free survival curve and overall survival curve according to the modified PVN classification for all the patients in the present study (**A** and **B**). The disease-free survival curve (**A**) and the overall survival curve (**B**) for each class significantly decrease according to the increasing order of the classifications (*P*\<0.001).](bjc2011279f2){#fig2}

###### Multivariate analyses for tumour recurrence and tumour-related death in all the invasive ductal carcinoma patients (*n*=1042)

                                                                                 **Tumour recurrence**  **Tumour-related death**                                                           
  ----------------------------------------------------------------------------- ----------------------- -------------------------- ----------------- --------- --------- ----------------- ---------
  *Fibrotic focus, diameter (mm)*                                                                                                                                                          
   Absent                                                                                 667           95 (14)                        Referent                42 (6)        Referent       
   ⩽8                                                                                     221           37 (17)                     1.0 (0.7--1.5)   0.914     15 (7)     1.0 (0.5--1.9)   0.999
   \>8                                                                                    154           52 (34)                     1.9 (1.4--2.6)   \<0.001   32 (21)    2.2 (1.3--3.6)   0.003
                                                                                                                                                                                            
  *Grading system for lymph vessel tumour emboli*                                                                                                                                          
   Grade 0                                                                                666           74 (11)                        Referent                30 (5)        Referent       
   Grade 1                                                                                250           43 (17)                     1.6 (0.9--2.6)   0.074     18 (7)     1.4 (0.8--2.5)   0.308
   Grade 2                                                                                97            46 (47)                     3.5 (2.4--5.1)   \<0.001   24 (25)    2.9 (1.6--5.2)   \<0.001
   Grade 3                                                                                29            21 (72)                     4.7 (2.8--8.0)   \<0.001   17 (59)    3.1 (1.5--6.3)   0.002
                                                                                                                                                                                            
  *Maximum dimension of metastatic carcinoma to the lymph nodes (mm)*                                                                                                                      
   no                                                                                     591           54 (9)                         Referent                17 (3)        Referent       
   ⩽20                                                                                    396           102 (26)                       Referent                53 (13)       Referent       
   \>20                                                                                   55            28 (51)                     1.8 (1.1--2.7)   0.011     19 (35)    1.9 (1.0--3.7)   0.040
                                                                                                                                                                                            
  *Number of apoptotic figures in blood vessel tumour emboli*                                                                                                                              
   Absent                                                                                 890           138 (16)                       Referent                61 (7)        Referent       
   ⩽2                                                                                     78            15 (19)                     2.6 (0.3--19.5)  0.359     6 (8)      2.6 (0.3--19.5)  0.359
   \>2                                                                                    74            21 (42)                     2.9 (2.0--4.4)   \<0.001   22 (30)    3.2 (1.8--5.6)   \<0.001
                                                                                                                                                                                            
  *Number of mitotic figures in metastatic carcinoma to lymph nodes*                                                                                                                       
   n0                                                                                     591           54 (9)                         Referent                17 (3)        Referent       
   ⩽5                                                                                     283           46 (16)                        Referent                17 (6)        Referent       
   \>5                                                                                    165           84 (51)                     2.6 (1.8--3.7)   \<0.001   55 (33)    3.6 (2.1--6.6)   \<0.001
                                                                                                                                                                                            
  *Nuclear feature of primary invasive tumours*                                                                                                                                            
   Small                                                                                  27            1 (4)                          Referent                1 (4)         Referent       
   Mod                                                                                    770           101 (13)                    1.5 (0.2--10.9)  0.697     38 (5)     0.3 (0.04--2.5)  0.265
   Marked                                                                                 245           82 (33)                     1.5 (1.1--2.1)   0.012     50 (20)    1.3 (0.5--3.0)   0.576
                                                                                                                                                                                            
  *Allred scores for progesterone receptors in primary invasive tumour cells*                                                                                                              
   0 or 2                                                                                 183           48 (26)                        Referent                24 (13)       Referent       
   3--6                                                                                   303           58 (19)                     0.9 (0.5--1.5)   0.553     36 (12)    1.3 (0.6--2.6)   0.518
   7 or 8                                                                                 556           78 (14)                     0.9 (0.5--1.5)   0.717     29 (5)     0.5 (0.3--0.8)   0.007
                                                                                                                                                                                            
  *Number of extranodal blood vessel tumour emboli*                                                                                                                                        
   no                                                                                     591           54 (9)                         Referent                17 (3)        Referent       
   ⩽2                                                                                     423           17 (4)                         Referent                11 (3)        Referent       
   \>2                                                                                    28            19 (68)                     1.5 (0.8--2.8)   0.256     18 (65)    1.9 (1.0--3.6)   0.036

Abbreviations: HR=hazard ratio; CI=confidence interval; no=no nodal metastasis; small=small and regular in size; mod=moderate variation; marked=marked variation.

###### Multivariate analyses for tumour recurrence and tumour-related death in invasive ductal carcinoma patients without nodal metastases

  **Patients without nodal metastasis (*n*=591)**                                                                                                                
  --------------------------------------------------------------------------------- ----- --------- ------------------- --------- --------- -------------------- -------
  *Grading system for lymph vessel tumour emboli*                                                                                                                
   Grade 0                                                                           465   38 (8)        Referent                  11 (2)         Referent           
   Grade 1                                                                           111    9 (8)     0.9 (0.4--1.8)      0.690     4 (4)      1.6 (0.5--5.2)     0.474
   Grade 2                                                                           14    6 (43)     5.9 (2.4--14.2)    \<0.001    1 (7)     2.4 (0.3--20.8)     0.437
   Grade 3                                                                            1    1 (100)   42.8 (5.3--344.6)   \<0.001   1 (100)   96.0 (5.9--1545.7)   0.001
                                                                                                                                                                     
  *Number of mitotic figures in primary invasive tumours (/10 high-power fields)*                                                                                
   ⩽9                                                                                285   12 (4)        Referent                  1 (0.4)        Referent           
   \>9--⩽19                                                                          153   15 (10)    1.4 (0.6--3.2)      0.467     5 (3)     6.6 (0.7--60.1)     0.093
   \>19                                                                              153   27 (18)     2.0 (1--3.5)       0.025    11 (7)    12.4 (1.2--125.5)    0.035
                                                                                                                                                                     
  *Fibrotic focus, diameter (mm)*                                                                                                                                
   Absent                                                                            415   33 (8)        Referent                  11 (3)         Referent           
   ⩽8                                                                                114    8 (7)     0.8 (0.3--1.8)      0.571     2 (2)      0.5 (0.1--3.2)     0.476
   \>8                                                                               62    13 (21)    2.3 (1.2--4.6)      0.011     4 (7)      1.1 (0.3--4.4)     0.908
                                                                                                                                                                     
  *HER 2 category in primary invasive tumour cells*                                                                                                              
   0 or 1                                                                            424   28 (7)        Referent                   8 (2)         Referent           
   2                                                                                 104   12 (12)    1.3 (0.6--3.1)      0.483     4 (4)      1.6 (0.4--7.6)     0.526
   3                                                                                 63    14 (22)    2.0 (1.1--3.9)      0.032     5 (8)     2.7 (0.7--10.2)     0.138
                                                                                                                                                                     
  *Number of apoptotic figures in blood vessel tumour emboli*                                                                                                    
   Absent                                                                            528   46 (9)        Referent                  14 (3)         Referent           
   ⩽2                                                                                33     3 (9)     1.1 (0.3--3.6)      0.916       0           Referent           
   \>2                                                                               30    5 (17)     2.0 (0.7--5.3)      0.175    3 (10)     4.1 (1.1--16.0)     0.041

Abbreviations: HR=hazard ratio; CI=confidence interval.

###### Multivariate analyses for tumour recurrence and tumour-related death in invasive ductal carcinoma patients with nodal metastases

  **Patients with nodal metastases (*n*=451)**                                                                                                               
  -------------------------------------------------------------------------------- ----- ---------- ----------------- --------- --------- ------------------ ---------
  *Fibrotic focus, diameter (mm)*                                                                                                                            
   Absent                                                                           252   62 (25)       Referent                 31 (12)       Referent           
   ⩽8                                                                               107   29 (27)    1.5 (0.8--2.8)     0.175    13 (12)    1.0 (0.5--2.2)     0.945
   \>8                                                                              92    39 (42)    1.6 (1.1--2.4)     0.020    28 (30)    2.0 (1.2--3.3)     0.005
                                                                                                                                                                  
  *Grading system for lymph vessel tumour emboli*                                                                                                            
   Grade 0                                                                          201   36 (18)       Referent                 19 (10)       Referent           
   Grade 1                                                                          139   34 (25)    1.6 (0.9--2.7)     0.083    14 (10)    1.1 (0.5--2.5)     0.740
   Grade 2                                                                          83    40 (48)    2.6 (1.7--3.9)    \<0.001   23 (28)    2.8 (1.6--5.0)    \<0.001
   Grade 3                                                                          28    20 (71)    3.4 (1.9--6.0)    \<0.001   16 (57)    3.6 (1.9--7.1)    \<0.001
                                                                                                                                                                  
  *Maximum dimension of metastatic carcinoma to the lymph nodes (mm)*                                                                                        
   ⩽20                                                                              396   102 (26)      Referent                 53 (13)       Referent           
   \>20                                                                             55    28 (51)    1.6 (1.0--2.4)     0.044    19 (35)    2.0 (1.1--3.8)     0.029
                                                                                                                                                                  
  *Number of apoptotic figures in blood vessel tumour emboli*                                                                                                
   Absent                                                                           362   92 (25)       Referent                 47 (13)       Referent           
   ⩽2                                                                               45    12 (27)    1.5 (0.2--12.9)    0.693    6 (13)    9.7 (0.9--111.1)    0.065
   \>2                                                                              24    26 (59)    3.1 (1.9--4.9)    \<0.001   19 (43)    3.2 (1.9--5.6)    \<0.001
                                                                                                                                                                  
  *Number of extranodal blood vessel tumour emboli*                                                                                                          
   ⩽2                                                                               423   111 (26)      Referent                 54 (13)       Referent           
   \>2                                                                              28    19 (68)    1.8 (1.1--3.2)     0.034    18 (65)    2.1 (1.1--3.8)     0.019
                                                                                                                                                                  
  *Number of mitotic figures in metastatic carcinoma to lymph nodes*                                                                                         
   ⩽5                                                                               286   46 (16)       Referent                 17 (6)        Referent           
   \>5                                                                              165   84 (51)    2.7 (1.8--3.9)    \<0.001   55 (33)    3.4 (1.9--6.2)    \<0.001
                                                                                                                                                                  
  *Grade of stromal fibrosis in metastatic mammary carcinoma to the lymph nodes*                                                                             
   None                                                                             101   19 (19)       Referent                  9 (9)        Referent           
   Mild                                                                             177   38 (22)    0.8 (0.4--1.4)     0.354    20 (11)    0.6 (0.2--1.6)     0.330
   Mod                                                                              137   54 (39)    1.2 (0.6--2.1)     0.666    32 (23)    1.0 (0.4--2.6)     0.999
   Severe                                                                           36    19 (53)    1.9 (1.2--3.2)     0.009    11 (31)    0.7 (0.2--2.4)     0.554
                                                                                                                                                                  
  *Allred scores for progesterone receptors in primary invasive tumour cells*                                                                                
   0 or 2                                                                           79    33 (42)       Referent                 18 (23)       Referent           
   3--6                                                                             134   40 (30)    0.8 (0.5--1.4)     0.442    30 (22)    1.1 (0.5--2.2)     0.862
   7 or 8                                                                           238   57 (24)    0.9 (0.5--1.6)     0.704    24 (10)    0.5 (0.3--0.9)     0.010

Abbreviations: HR=hazard ratio; CI=confidence interval; mod=moderate variation.

###### Parameters of the modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast

  **Parameters**                                                                                 **Scores**
  --------------------------------------------------------------------------------------------- -------------
  1\. Fibrotic focus, diameter, in primary invasive tumours                                     
  Absent/⩽ 8 mm *vs* \>8 mm                                                                       0 *vs* 1
  2\. Nuclear feature of primary invasive ductal carcinomas                                     
  Small/moderate *vs* marked                                                                      0 *vs* 1
  3\. Number of mitotic figures in primary invasive ductal carcinomas (/10 high-power fields)   
  ⩽19 *vs* \>19                                                                                   0 *vs* 1
  4\. Grading system for lymph vessel tumour emboli                                             
  Grades 0, 1, 2, and 3                                                                             0--3
  5\. Number of apoptotic figures in blood vessel tumour emboli                                 
  Absent/⩽2 *vs* \>2                                                                              0 *vs* 1
  6\. Grade of stromal fibrosis in metastatic mammary carcinoma to the lymph nodes              
  n0/none/mild/moderate *vs* severe                                                               0 *vs* 1
  7\. Maximum dimension of metastatic carcinoma to the lymph nodes (mm)                         
  n0/⩽20 *vs* \>20                                                                                0 *vs* 1
  8\. Number of extranodal blood vessel tumour emboli                                           
  n0/⩽2 *vs* \>2                                                                                  0 *vs* 1
  9\. Number of mitotic figures in metastatic carcinoma to the lymph nodes                      
  n0/⩽5 *vs* \>5                                                                                  0 *vs* 1
                                                                                                       
                                                                                                 Total 0--11

Abbreviation: no=no metastatic tumour.

###### Tumour recurrence and death rates according to the modified primary tumour/vessel tumour/nodal tumour classification, the UICC pTNM stage classification, and the Nottingham Prognostic Index among all the patients with invasive ductal carcinoma (*n*=1042)

  **Primary tumour/vessel tumour/nodal tumour classification**                                        
  -------------------------------------------------------------- ------ --------- --------- --------- ---------
  Class 0 (0)                                                     349    11 (3)              2 (0.6)       
  Class 1 (1/2)                                                   466    66 (14)   \<0.001   23 (5)     0.018
  Class 2 (3/4)                                                   151    56 (37)    0.005    26 (17)    0.002
  Class 3 (5)                                                      39    22 (56)    0.001    11 (28)    0.030
  Class 4 (6/7)                                                    29    21 (72)    0.390    19 (66)    0.505
  Class 5 (8--11)                                                  8     8 (100)    0.047    8 (100)    0.111
                                                                                                           
  *UICC pTNM stage classification*                                                                    
   Stage I (IA and IB)                                            352    26 (7)               9 (3)        
   Stage II (IIA and IIB)                                         494    87 (18)   \<0.001   34 (7)     0.004
   Stage IIIA and IIIB                                            148    42 (28)    0.003    25 (17)   \<0.001
   Stage IIIC                                                      48    29 (60)   \<0.001   21 (44)   \<0.001
                                                                                                           
  *Nottingham Prognostic Index*                                                                       
   Excellent prognostic group                                     130    1 (0.8)                0          
   Good prognostic group                                          240    15 (6)     0.015     3 (1)     0.235
   Moderate prognostic group I                                    252    38 (15)    0.002    10 (4)     0.069
   Moderate prognostic group II                                   240    45 (19)    0.175    23 (10)    0.009
   Poor prognostic group                                          118    48 (41)   \<0.001   23 (19)    0.009
   Very poor prognostic group                                      62    37 (60)    0.007    30 (48)   \<0.001
                                                                                                           
  Total                                                           1042     169                 67          

Abbreviations: TRR=tumour recurrence rate; MR=mortality rate.

###### Multivariate analyses for disease-free and overall survival for the modified primary tumour/vessel tumour/nodal tumour classification, the UICC pTNM stage classification, and the Nottingham Prognostic Index in patients with invasive ductal carcinoma according to nodal status or hormone receptor status

                                                                                                            **Disease-free survival**   **Overall survival**                   
  -------------------------------------------------------------------------------------------------------- --------------------------- ---------------------- ---------------- ---------
  *Patients with invasive ductal carcinoma without nodal metastasis (*n=*592)*                                                                                                 
  Model 2                                                                                                                                                                      
   PVN (0--5)                                                                                                    2.1 (1.3--3.5)                0.003           3.4 (1.5--7.7)    0.004
   NPI (EPG, GPG, MPGI, MPGII, PPG, VPG)                                                                         1.4 (0.9--2.1)                0.065           1.3 (0.7--2.5)    0.449
                                                                                                                                                                                    
  *Patients with invasive ductal carcinoma with nodal metastasis (*n=*450)*                                                                                                    
  Model 1                                                                                                                                                                      
   PVN (0--5)                                                                                                    2.2 (1.9--2.5)               \<0.001          2.4 (1.9--2.9)   \<0.001
   pTNM (I, II, IIIAB, IIIC)                                                                                     1.2 (0.9--1.5)                0.180           1.2 (0.9--1.7)    0.232
  Model 2                                                                                                                                                                      
   PVN (0--5)                                                                                                    2.2 (1.8--2.6)               \<0.001          2.1 (1.7--2.7)   \<0.001
   NPI (EPG, GPG, MPGI, MPGII, PPG, VPG)                                                                         1.1 (0.9--1.4)                0.259           1.5 (1.1--2.0)    0.024
                                                                                                                                                                                    
  *Patients with invasive ductal carcinoma who were completely negative for hormone receptors (*n=*125)*                                                                       
  Model 1                                                                                                                                                                      
   PVN (0--5)                                                                                                    2.3 (1.6--3.3)               \<0.001          2.6 (1.7--4.3)   \<0.001
   pTNM (I, II, IIIAB, IIIC)                                                                                     1.3 (0.8--2.1)                0.344           1.3 (0.6--2.6)    0.548
  Model 2                                                                                                                                                                      
   PVN (0--5)                                                                                                    2.5 (1.7--3.6)               \<0.001          2.4 (1.5--4.1)   \<0.001
   NPI (EPG, GPG, MPGI, MPGII, PPG, VPG)                                                                         1.1 (0.7--1.6)                0.779           1.3 (0.7--2.5)    0.426
                                                                                                                                                                                    
  *Patients with invasive ductal carcinoma who were positive for one or two hormone receptors (*n=*917)*                                                                       
  Model 1                                                                                                                                                                      
   PVN (0--5)                                                                                                    2.3 (1.9--2.6)               \<0.001          2.4 (2.0--3.0)   \<0.001
   pTNM (I, II, IIIAB, IIIC)                                                                                     1.3 (1.0--1.6)                0.024           1.2 (0.9--1.6)    0.206
  Model 2                                                                                                                                                                      
   PVN (0--5)                                                                                                    2.0 (1.7--2.4)               \<0.001          2.1 (1.6--2.7)   \<0.001
   NPI (EPG, GPG, MPGI, MPGII, PPG, VPG)                                                                         1.3 (1.1--1.6)                0.002           1.4 (1.1--1.9)    0.013

Abbreviations: HR=hazard ratio; CI=confidence interval; PVN=modified primary tumour/vessel tumour/nodal tumour; NPI=Nottingham Prognostic Index; EPG=excellent prognostic group; GPG=good prognostic group; MPGI=moderate prognostic group I; MPGII=moderate prognostic group II; PPG=poor prognostic group; VPG=very poor prognostic group; pTNM=UICC pTNM; IIIAB=UICC pTNM stages IIIA and IIIB.

###### Multivariate analyses for disease-free and overall survival for the modified primary tumour/vessel tumour/nodal tumour classification, the UICC pTNM stage classification, and the Nottingham Prognostic Index in patients with invasive ductal carcinoma according to adjuvant therapy status

                                                                                            **Disease-free survival**   **Overall survival**                     
  ----------------------------------------------------------------------------------------- --------------------------- ---------------------- ----------------- ---------
  *Patients with invasive ductal carcinoma not treated with adjuvant therapy (*n=*169)*                                                                          
  Model 1                                                                                                                                                        
   PVN (0--5)                                                                               2.4 (1.4--4.1)              0.001                         NA          
   pTNM (I, II, IIIAB, IIIC)                                                                1.2 (0.6--2.5)              0.653                         NA          
  Model 2                                                                                                                                                        
   PVN (0--5)                                                                               2.1 (1.2--3.7)              0.012                         NA          
   NPI (EPG, GPG, MPGI, MPGII, PPG, VPG)                                                    1.5 (0.8--2.4)              0.120                         NA          
                                                                                                                                                                  
  *Patients with invasive ductal carcinoma treated with endocrine therapy (*n=*281)*                                                                             
  Model 1                                                                                                                                                        
   PVN (0--5)                                                                               3.4 (2.5--4.8)              \<0.001                 5.6 (2.8--11.1)  \<0.001
   pTNM (I, II, IIIAB, IIIC)                                                                1.3 (0.8--2.1)              0.291                   0.5 (0.2--1.5)   0.205
  Model 2                                                                                                                                                        
   PVN (0--5)                                                                               2.9 (1.9--4.5)              \<0.001                 4.7 (2.2--10.4)  \<0.001
   NPI (EPG, GPG, MPGI, MPGII, PPG, VPG)                                                    1.3 (0.9--1.8)              0.128                   0.8 (0.4--1.8)   0.662
                                                                                                                                                                  
  *Patients with invasive ductal carcinoma treated with chemoendocrine therapy (*n=*375)*                                                                        
  Model 1                                                                                                                                                        
   PVN (0--5)                                                                               2.0 (1.6--2.5)              \<0.001                 2.1 (1.5--3.0)   \<0.001
   pTNM (I, II, IIIAB, IIIC)                                                                1.4 (0.9--1.9)              0.057                   1.4 (0.9--2.3)   0.115
  Model 2                                                                                                                                                        
   PVN (0--5)                                                                               1.7 (1.3--2.3)              \<0.001                 1.7 (1.1--2.7)   0.011
   NPI (EPG, GPG, MPGI, MPGII, PPG, VPG)                                                    1.4 (1.1--1.8)              0.012                   1.6 (1.1--2.5)   0.020
                                                                                                                                                                  
  *Patients with invasive ductal carcinoma treated with chemotherapy (*n=*217)*                                                                                  
  Model 1                                                                                                                                                        
   PVN (0--5)                                                                               2.1 (1.6--2.8)              \<0.001                 2.2 (1.7--2.8)   \<0.001
   pTNM (I, II, IIIAB, IIIC)                                                                1.3 (0.9--2.0)              0.188                   1.3 (0.9--1.8)   0.152
  Model 2                                                                                                                                                        
   PVN (0--5)                                                                               2.3 (1.7--3.0)              \<0.001                 2.0 (1.5--2.7)   \<0.001
   NPI (EPG, GPG, MPGI, MPGII, PPG, VPG)                                                    1.1 (0.8--1.5)              0.619                   1.4 (0.9--2.1)   0.133

Abbreviations: HR=hazard ratio; CI=confidence interval; PVN=modified primary tumour/vessel tumour/nodal tumour; NPI=Nottingham Prognostic Index; EPG=excellent prognostic group; GPG=good prognostic group; MPGI=moderate prognostic group I; MPGII=moderate prognostic group II; PPG=poor prognostic group; VPG=very poor prognostic group; pTNM=UICC pTNM; IIIAB=UICC pTNM stages IIIA and IIIB; NA=not available.
